Opendata, web and dolomites

MAINTRAC-Auto

MAINTRAC-Auto: Automatization and validation of a liquid biopsy assay “Maintrac-AUTO CTC-analyser” for predictive real time monitoring and success control of solid tumor cancer therapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MAINTRAC-Auto project word cloud

Explore the words cloud of the MAINTRAC-Auto project. It provides you a very rough idea of what is the project "MAINTRAC-Auto" about.

therapies    treatment    reimbursement    sales    2020    ineffective    circulating    specialists    commercially    diagnostics    auto    families    oncology    us    obvious    patients    prognosis    automatic    efficiency    manual    estimate    maintenance    automated    monitoring    12bn    ctc    approved    health    offers    assays    drastically    care    progression    reducing    individualize    acceptance    validation    launch    death    course    primary    clinically    forecasts    therapy    biomarker    meanwhile    equivalence    public    appropriate    market    indicator    cancer    causes    symptoms    relevance    penetration    assay    maintrac    track    revenue    ctcs    demand    implications    initial    suffering    economic    disease    direct    relapse    clinical    model    meet    adequately    innovative    patient    tumor    arise    standardized    breast    diseases    regulatory    substantially    analyser    business    series    big    individual    cells    precision    savings    diagnose    upscaling    worldwide    innovation    readiness    effectiveness   

Project "MAINTRAC-Auto" data sheet

The following table provides information about the project.

Coordinator
SIMFO SPEZIELLE IMMUNOLOGIE FORSCHUNG UND ENTWICKLUNG GMBH 

Organization address
address: KURPROMENADE 2
city: BAYREUTH
postcode: 95448
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Project website http://www.simfo.de
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-03-01   to  2016-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SIMFO SPEZIELLE IMMUNOLOGIE FORSCHUNG UND ENTWICKLUNG GMBH DE (BAYREUTH) coordinator 50˙000.00

Map

 Project objective

Worldwide cancer is one of the leading causes of death and the need for more effective therapies is crucial. New precision diagnostics can identify and characterize the disease to individualize the therapy throughout the course of cancer, like our clinically approved Maintrac-CTC assay. Maintrac-CTC can track circulating tumor cells (CTCs) even in primary cancer patients to estimate prognosis and diagnose relapse well before clinical symptoms arise. Meanwhile a fully automated Maintrac AUTO analyser was established and offers a standardized state-of-art biomarker system for direct and better monitoring of disease progression and effectiveness i.e. of the maintenance therapy in breast cancer. We aim to drastically increase both effectiveness (selection of treatment most adequately for individual cancer type and phase) and efficiency (early indicator for the response level to an initial therapy) to avoid ineffective therapies, savings cost for the health care system and substantially reducing patient suffering. The objectives of the innovation project are to achieve series-production readiness and launch the system commercially with the best business model. We aim for acceptance of Maintrac CTC assays by oncology specialists through clinical validation and to achieve reimbursement by public authorities for upscaling and market penetration. In phase 1 we will show equivalence of the automatic system to the established manual method and meet regulatory requirements. In addition business opportunities and appropriate sales model will be evaluated. Forecasts for overall CTC biomarker market estimate a big market with a high demand for innovative products with expected revenue potential of US$ 12bn in 2020. Due to the obvious relevance of cancer diseases for patients, their families as well as economic implications, Maintrac will have an important impact on future cancer disease management.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MAINTRAC-AUTO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MAINTRAC-AUTO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More